514 related articles for article (PubMed ID: 11054326)
1. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis.
Jaffe GJ; Ben-Nun J; Guo H; Dunn JP; Ashton P
Ophthalmology; 2000 Nov; 107(11):2024-33. PubMed ID: 11054326
[TBL] [Abstract][Full Text] [Related]
2. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
Chieh JJ; Carlson AN; Jaffe GJ
Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis.
Jaffe GJ; McCallum RM; Branchaud B; Skalak C; Butuner Z; Ashton P
Ophthalmology; 2005 Jul; 112(7):1192-8. PubMed ID: 15921758
[TBL] [Abstract][Full Text] [Related]
4. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results.
Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS
Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623
[TBL] [Abstract][Full Text] [Related]
5. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.
Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T;
Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128
[TBL] [Abstract][Full Text] [Related]
6. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
7. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma.
Malone PE; Herndon LW; Muir KW; Jaffe GJ
Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158
[TBL] [Abstract][Full Text] [Related]
8. Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis.
Jaffe GJ
Am J Ophthalmol; 2008 Apr; 145(4):667-675. PubMed ID: 18226800
[TBL] [Abstract][Full Text] [Related]
9. The safety profile of long-term, high-dose intraocular corticosteroid delivery.
Holekamp NM; Thomas MA; Pearson A
Am J Ophthalmol; 2005 Mar; 139(3):421-8. PubMed ID: 15767049
[TBL] [Abstract][Full Text] [Related]
10. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
11. Pars plana vitrectomy, fluocinolone acetonide implantation, and silicone oil infusion for the treatment of chronic, refractory uveitic hypotony.
Dayani PN; Chow J; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2011 Nov; 152(5):849-56.e1. PubMed ID: 21794844
[TBL] [Abstract][Full Text] [Related]
12. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
[TBL] [Abstract][Full Text] [Related]
13. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study.
Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group
Ophthalmology; 2015 Oct; 122(10):1976-86. PubMed ID: 26298718
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial.
; Kempen JH; Altaweel MM; Holbrook JT; Jabs DA; Louis TA; Sugar EA; Thorne JE
Ophthalmology; 2011 Oct; 118(10):1916-26. PubMed ID: 21840602
[TBL] [Abstract][Full Text] [Related]
15. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert).
Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL
Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487
[TBL] [Abstract][Full Text] [Related]
16. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant.
Parekh A; Srivastava S; Bena J; Albini T; Nguyen QD; Goldstein DA
JAMA Ophthalmol; 2015 May; 133(5):568-73. PubMed ID: 25719937
[TBL] [Abstract][Full Text] [Related]
17. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis.
Arcinue CA; Cerón OM; Foster CS
J Ocul Pharmacol Ther; 2013 Jun; 29(5):501-7. PubMed ID: 23297752
[TBL] [Abstract][Full Text] [Related]
18. Combined Ahmed Glaucoma Valve Placement, Intravitreal Fluocinolone Acetonide Implantation and Cataract Extraction for Chronic Uveitis.
Chang IT; Gupta D; Slabaugh MA; Vemulakonda GA; Chen PP
J Glaucoma; 2016 Oct; 25(10):842-846. PubMed ID: 27300641
[TBL] [Abstract][Full Text] [Related]
19. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial.
Friedman DS; Holbrook JT; Ansari H; Alexander J; Burke A; Reed SB; Katz J; Thorne JE; Lightman SL; Kempen JH;
Ophthalmology; 2013 Aug; 120(8):1571-9. PubMed ID: 23601801
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of fluocinolone acetonide intravitreal implant (0.59 mg) in birdshot retinochoroidopathy.
Bajwa A; Aziz K; Foster CS
Retina; 2014 Nov; 34(11):2259-68. PubMed ID: 24999722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
